BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee JM, Ledermann JA, Kohn EC. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann Oncol. 2014;25:32-40. [PMID: 24225019 DOI: 10.1093/annonc/mdt384] [Cited by in Crossref: 206] [Cited by in F6Publishing: 159] [Article Influence: 25.8] [Reference Citation Analysis]
Number Citing Articles
1 Danza K, De Summa S, Pinto R, Pilato B, Palumbo O, Carella M, Popescu O, Digennaro M, Lacalamita R, Tommasi S. TGFbeta and miRNA regulation in familial and sporadic breast cancer. Oncotarget 2017;8:50715-23. [PMID: 28881597 DOI: 10.18632/oncotarget.14899] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
2 Elzek MA, Rodland KD. Proteomics of ovarian cancer: functional insights and clinical applications. Cancer Metastasis Rev 2015;34:83-96. [PMID: 25736266 DOI: 10.1007/s10555-014-9547-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
3 Lee JM, Hays JL, Chiou VL, Annunziata CM, Swisher EM, Harrell MI, Yu M, Gordon N, Sissung TM, Ji J, Figg WD, Minasian L, Lipkowitz S, Wood BJ, Doroshow J, Kohn EC. Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. Oncotarget 2017;8:79175-87. [PMID: 29108297 DOI: 10.18632/oncotarget.16577] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
4 Andrei P, Battuello P, Grasso G, Rovera E, Tesio N, Bardelli A. Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. Semin Cancer Biol 2021:S1044-579X(21)00108-5. [PMID: 33848627 DOI: 10.1016/j.semcancer.2021.04.007] [Reference Citation Analysis]
5 Tung NM, Garber JE. BRCA1/2 testing: therapeutic implications for breast cancer management. Br J Cancer 2018;119:141-52. [PMID: 29867226 DOI: 10.1038/s41416-018-0127-5] [Cited by in Crossref: 69] [Cited by in F6Publishing: 47] [Article Influence: 23.0] [Reference Citation Analysis]
6 Yang Y, Li X, Hao L, Jiang D, Wu B, He T, Tang Y. The diagnostic value of DNA repair gene in breast cancer metastasis. Sci Rep 2020;10:19626. [PMID: 33184404 DOI: 10.1038/s41598-020-76577-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Hernandez AL, Young CD, Bian L, Weigel K, Nolan K, Frederick B, Han G, He G, Devon Trahan G, Rudolph MC, Jones KL, Oweida AJ, Karam SD, Raben D, Wang XJ. PARP Inhibition Enhances Radiotherapy of SMAD4-Deficient Human Head and Neck Squamous Cell Carcinomas in Experimental Models. Clin Cancer Res 2020;26:3058-70. [PMID: 32139402 DOI: 10.1158/1078-0432.CCR-19-0514] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Synnott NC, Murray A, McGowan PM, Kiely M, Kiely PA, O'Donovan N, O'Connor DP, Gallagher WM, Crown J, Duffy MJ. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer? Int J Cancer 2017;140:234-46. [PMID: 27615392 DOI: 10.1002/ijc.30425] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 8.6] [Reference Citation Analysis]
9 Li X, Fang T, Xu S, Jin P, Zhou D, Wang Z, Li H, Yang Z, Chen G, Zheng X, Xia Y, Wei X, Zhang Z, Yang X, Wang Y, Gao Q. PARP inhibitors promote stromal fibroblast activation by enhancing CCL5 autocrine signaling in ovarian cancer. NPJ Precis Oncol 2021;5:49. [PMID: 34108603 DOI: 10.1038/s41698-021-00189-w] [Reference Citation Analysis]
10 Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, Balgobind AV, Wind K, Gracanin A, Begthel H, Korving J, van Boxtel R, Duarte AA, Lelieveld D, van Hoeck A, Ernst RF, Blokzijl F, Nijman IJ, Hoogstraat M, van de Ven M, Egan DA, Zinzalla V, Moll J, Boj SF, Voest EE, Wessels L, van Diest PJ, Rottenberg S, Vries RGJ, Cuppen E, Clevers H. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell 2018; 172: 373-386. e10. [PMID: 29224780 DOI: 10.1016/j.cell.2017.11.010] [Cited by in Crossref: 512] [Cited by in F6Publishing: 424] [Article Influence: 128.0] [Reference Citation Analysis]
11 Xie N, Tian C, Wu H, Yang X, Liu L, Li J, Xiao H, Gao J, Lu J, Hu X, Cao M, Shui Z, Tang Y, Wang X, Yang J, Hu ZY, Ouyang Q. FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients. Ther Adv Med Oncol 2020;12:1758835920915305. [PMID: 32499836 DOI: 10.1177/1758835920915305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Savage KI, Harkin DP. BRCA1, a 'complex' protein involved in the maintenance of genomic stability. FEBS J 2015;282:630-46. [PMID: 25400280 DOI: 10.1111/febs.13150] [Cited by in Crossref: 91] [Cited by in F6Publishing: 69] [Article Influence: 13.0] [Reference Citation Analysis]
13 Mateu-Jiménez M, Cucarull-Martínez B, Yelamos J, Barreiro E. Reduced tumor burden through increased oxidative stress in lung adenocarcinoma cells of PARP-1 and PARP-2 knockout mice. Biochimie 2016;121:278-86. [PMID: 26700152 DOI: 10.1016/j.biochi.2015.11.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
14 Sonnenblick A, de Azambuja E, Azim HA Jr, Piccart M. An update on PARP inhibitors--moving to the adjuvant setting. Nat Rev Clin Oncol 2015;12:27-41. [PMID: 25286972 DOI: 10.1038/nrclinonc.2014.163] [Cited by in Crossref: 234] [Cited by in F6Publishing: 183] [Article Influence: 33.4] [Reference Citation Analysis]
15 Ahn DH, Ramanathan RK, Bekaii-Saab T. Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma. Cancers (Basel) 2018;10:E193. [PMID: 29891787 DOI: 10.3390/cancers10060193] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
16 Li L, Xiang YX, Yang GP, Zhang XF, Yang XY, Yang S, Huang J. Pharmacokinetic effects of proton pump inhibitors on the novel PARP inhibitor fluzoparib: a single-arm, fixed-sequence trial in male healthy volunteers. Invest New Drugs 2021;39:796-802. [PMID: 33420642 DOI: 10.1007/s10637-020-01034-w] [Reference Citation Analysis]
17 Michels J, Adam J, Goubar A, Obrist F, Damotte D, Robin A, Alifano M, Vitale I, Olaussen KA, Girard P, Cremer I, Castedo M, Soria JC, Kroemer G. Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer. Ann Oncol 2015;26:2470-7. [PMID: 26387143 DOI: 10.1093/annonc/mdv393] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
18 Motea EA, Huang X, Singh N, Kilgore JA, Williams NS, Xie XJ, Gerber DE, Beg MS, Bey EA, Boothman DA. NQO1-dependent, Tumor-selective Radiosensitization of Non-small Cell Lung Cancers. Clin Cancer Res 2019;25:2601-9. [PMID: 30617135 DOI: 10.1158/1078-0432.CCR-18-2560] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
19 Katiyi A, Zorea J, Halstuch A, Elkabets M, Karabchevsky A. Surface roughness-induced absorption acts as an ovarian cancer cells growth sensor-monitor. Biosens Bioelectron 2020;161:112240. [PMID: 32365013 DOI: 10.1016/j.bios.2020.112240] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Chen M, Huang H, Wu K, Liu Y, Jiang L, Li Y, Tang G, Peng J, Cao X. Synthesis and evaluation of 2-(4-[4-acetylpiperazine-1-carbonyl] phenyl)-1H-benzo[d]imidazole-4-carboxamide derivatives as potential PARP-1 inhibitors and preliminary study on structure-activity relationship. Drug Dev Res 2021. [PMID: 34151456 DOI: 10.1002/ddr.21843] [Reference Citation Analysis]
21 Vos S, Moelans CB, van Diest PJ. BRCA promoter methylation in sporadic versus BRCA germline mutation-related breast cancers. Breast Cancer Res 2017;19:64. [PMID: 28569220 DOI: 10.1186/s13058-017-0856-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
22 Weiderpass E, Tyczynski JE. Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation. Mol Diagn Ther 2015;19:351-64. [PMID: 26476542 DOI: 10.1007/s40291-015-0168-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
23 Zhang H, Li L, Wang Y, Yin CC, Xie Y, Liu X, Ding H, Tian Z, Shen J, He L, Xia M, Ma X, Wu L. Functional analysis of BRCT missense mutations in BRCA1-mutated Chinese Han familial breast cancer. Oncol Lett 2017;14:5839-44. [PMID: 29113215 DOI: 10.3892/ol.2017.7003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Guo D, Zhao Y, Wang N, You N, Zhu W, Zhang P, Ren Q, Yin J, Cheng T, Ma X. GADD45g acts as a novel tumor suppressor and its activation confers new combination regimens for the treatment of AML. Blood 2021:blood. [PMID: 33945602 DOI: 10.1182/blood.2020008229] [Reference Citation Analysis]
25 Eskander RN, Tewari KS. PARP inhibition and synthetic lethality in ovarian cancer. Expert Rev Clin Pharmacol 2014;7:613-22. [PMID: 24984781 DOI: 10.1586/17512433.2014.930662] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
26 Berger NA, Besson VC, Boulares AH, Bürkle A, Chiarugi A, Clark RS, Curtin NJ, Cuzzocrea S, Dawson TM, Dawson VL, Haskó G, Liaudet L, Moroni F, Pacher P, Radermacher P, Salzman AL, Snyder SH, Soriano FG, Strosznajder RP, Sümegi B, Swanson RA, Szabo C. Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases. Br J Pharmacol 2018;175:192-222. [PMID: 28213892 DOI: 10.1111/bph.13748] [Cited by in Crossref: 100] [Cited by in F6Publishing: 92] [Article Influence: 25.0] [Reference Citation Analysis]
27 Eetezadi S, Evans JC, Shen Y, De Souza R, Piquette-miller M, Allen C. Ratio-Dependent Synergism of a Doxorubicin and Olaparib Combination in 2D and Spheroid Models of Ovarian Cancer. Mol Pharmaceutics 2018;15:472-85. [DOI: 10.1021/acs.molpharmaceut.7b00843] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
28 Evans DG, Harkness EF, Howel S, Woodward ER, Howell A, Lalloo F. Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2018;167:779-85. [PMID: 29116468 DOI: 10.1007/s10549-017-4557-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
29 Kim Y, Kim A, Sharip A, Sharip A, Jiang J, Yang Q, Xie Y. Reverse the Resistance to PARP Inhibitors. Int J Biol Sci 2017;13:198-208. [PMID: 28255272 DOI: 10.7150/ijbs.17240] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 11.0] [Reference Citation Analysis]
30 Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib. Transl Oncol. 2017;10:190-196. [PMID: 28182994 DOI: 10.1016/j.tranon.2017.01.007] [Cited by in Crossref: 60] [Cited by in F6Publishing: 48] [Article Influence: 15.0] [Reference Citation Analysis]
31 Nicolas E, Arora S, Zhou Y, Serebriiskii IG, Andrake MD, Handorf ED, Bodian DL, Vockley JG, Dunbrack RL, Ross EA, Egleston BL, Hall MJ, Golemis EA, Giri VN, Daly MB. Systematic evaluation of underlying defects in DNA repair as an approach to case-only assessment of familial prostate cancer. Oncotarget 2015;6:39614-33. [PMID: 26485759 DOI: 10.18632/oncotarget.5554] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
32 Jones P, Wilcoxen K, Rowley M, Toniatti C. Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination. J Med Chem 2015;58:3302-14. [PMID: 25761096 DOI: 10.1021/jm5018237] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 11.5] [Reference Citation Analysis]
33 Fu L, Wang S, Wang X, Wang P, Zheng Y, Yao D, Guo M, Zhang L, Ouyang L. Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer. Sci Rep 2016;6:3. [PMID: 28442756 DOI: 10.1038/s41598-016-0007-2] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 5.4] [Reference Citation Analysis]
34 Evison BJ, Actis ML, Fujii N. A clickable psoralen to directly quantify DNA interstrand crosslinking and repair. Bioorg Med Chem 2016;24:1071-8. [PMID: 26833244 DOI: 10.1016/j.bmc.2016.01.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
35 Xu G, Chapman JR, Brandsma I, Yuan J, Mistrik M, Bouwman P, Bartkova J, Gogola E, Warmerdam D, Barazas M, Jaspers JE, Watanabe K, Pieterse M, Kersbergen A, Sol W, Celie PHN, Schouten PC, van den Broek B, Salman A, Nieuwland M, de Rink I, de Ronde J, Jalink K, Boulton SJ, Chen J, van Gent DC, Bartek J, Jonkers J, Borst P, Rottenberg S. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature 2015;521:541-4. [PMID: 25799992 DOI: 10.1038/nature14328] [Cited by in Crossref: 335] [Cited by in F6Publishing: 278] [Article Influence: 55.8] [Reference Citation Analysis]
36 Vos S, van Diest PJ, Moelans CB. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not? Critical Reviews in Oncology/Hematology 2018;127:29-41. [DOI: 10.1016/j.critrevonc.2018.05.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
37 Knezevic CE, Wright G, Rix LLR, Kim W, Kuenzi BM, Luo Y, Watters JM, Koomen JM, Haura EB, Monteiro AN, Radu C, Lawrence HR, Rix U. Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Cell Chem Biol 2016;23:1490-503. [PMID: 27866910 DOI: 10.1016/j.chembiol.2016.10.011] [Cited by in Crossref: 53] [Cited by in F6Publishing: 40] [Article Influence: 10.6] [Reference Citation Analysis]
38 Nakanishi K, Yamada T, Ishikawa G, Suzuki S. Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence. Front Oncol 2021;11:697952. [PMID: 34395265 DOI: 10.3389/fonc.2021.697952] [Reference Citation Analysis]
39 Monk BJ, Lorusso D, Italiano A, Kaye SB, Aracil M, Tanović A, D’incalci M. Trabectedin as a chemotherapy option for patients with BRCA deficiency. Cancer Treatment Reviews 2016;50:175-82. [DOI: 10.1016/j.ctrv.2016.09.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
40 Yang X, Ndawula C Jr, Zhou H, Gong X, Jin J. JF-305, a pancreatic cancer cell line is highly sensitive to the PARP inhibitor olaparib. Oncol Lett 2015;9:757-61. [PMID: 25621047 DOI: 10.3892/ol.2014.2762] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
41 Mehta R, Wood AC, Yu J, Kim R. Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. Expert Opin Investig Drugs 2021;30:451-61. [PMID: 33660569 DOI: 10.1080/13543784.2021.1898586] [Reference Citation Analysis]
42 Yamamoto KN, Hirota K, Takeda S, Haeno H. Evolution of pre-existing versus acquired resistance to platinum drugs and PARP inhibitors in BRCA-associated cancers. PLoS One 2014;9:e105724. [PMID: 25158060 DOI: 10.1371/journal.pone.0105724] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
43 Wakefield CE, Quinn VF, Fardell JE, Signorelli C, Tucker KM, Patenaude AF, Malkin D, Walwyn T, Alvaro F, Cohn RJ. Family history-taking practices and genetic confidence in primary and tertiary care providers for childhood cancer survivors. Pediatr Blood Cancer 2018;65. [PMID: 29286558 DOI: 10.1002/pbc.26923] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Kotsopoulos JBRCA Mutations and breast cancer prevention. Cancers (Basel). 2018;10. [PMID: 30572612 DOI: 10.3390/cancers10120524] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
45 Souid S, Aissaoui D, Srairi-Abid N, Essafi-Benkhadir K. Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response. Curr Drug Targets 2020;21:996-1007. [PMID: 31994460 DOI: 10.2174/1389450121666200128161733] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
46 Ko AH. Progress in the treatment of metastatic pancreatic cancer and the search for next opportunities. J Clin Oncol. 2015;33:1779-1786. [PMID: 25918299 DOI: 10.1200/jco.2014.59.7625] [Cited by in Crossref: 49] [Cited by in F6Publishing: 27] [Article Influence: 8.2] [Reference Citation Analysis]
47 Hou MF, Luo CW, Chang TM, Hung WC, Chen TY, Tsai YL, Chai CY, Pan MR. The NuRD complex-mediated p21 suppression facilitates chemoresistance in BRCA-proficient breast cancer. Exp Cell Res 2017;359:458-65. [PMID: 28842166 DOI: 10.1016/j.yexcr.2017.08.029] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
48 AbdelHamid S, El-Mesallamy H, Aziz HA, Zekri AR. Prognostic Impact of BRCA1 and BRCA2 Mutations on Long-Term Survival Outcomes in Egyptian Female Breast Cancer Patients. Biology (Basel) 2021;10:566. [PMID: 34206661 DOI: 10.3390/biology10070566] [Reference Citation Analysis]
49 Guo C, Zhang F, Wu X, Yu X, Wu X, Shi D, Wang L. BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo. International Journal of Biological Macromolecules 2020;150:238-45. [DOI: 10.1016/j.ijbiomac.2020.02.069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
50 Rizk VT, Walko CM, Brohl AS. Precision medicine approaches for the management of Ewing sarcoma: current perspectives. Pharmgenomics Pers Med 2019;12:9-14. [PMID: 30697061 DOI: 10.2147/PGPM.S170612] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
51 Kersten K, de Visser KE, van Miltenburg MH, Jonkers J. Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol Med 2017;9:137-53. [PMID: 28028012 DOI: 10.15252/emmm.201606857] [Cited by in Crossref: 172] [Cited by in F6Publishing: 128] [Article Influence: 43.0] [Reference Citation Analysis]
52 Wang Y, Zheng K, Huang Y, Xiong H, Su J, Chen R, Zou Y. PARP inhibitors in gastric cancer: beacon of hope. J Exp Clin Cancer Res 2021;40:211. [PMID: 34167572 DOI: 10.1186/s13046-021-02005-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Lee JM, Trepel JB, Choyke P, Cao L, Sissung T, Houston N, Yu M, Figg WD, Turkbey IB, Steinberg SM, Lee MJ, Ivy SP, Liu JF, Matulonis UA, Kohn EC. CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer. Front Oncol 2015;5:123. [PMID: 26082895 DOI: 10.3389/fonc.2015.00123] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
54 Deepak Singh D, Han I, Choi EH, Yadav DK. CRISPR/Cas9 based genome editing for targeted transcriptional control in triple-negative breast cancer. Comput Struct Biotechnol J 2021;19:2384-97. [PMID: 34025931 DOI: 10.1016/j.csbj.2021.04.036] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Zeng X, Jiang S, Ruan S, Guo Z, Guo J, Liu M, Ye C, Dong J. MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells. Mol Med Rep 2021;24:548. [PMID: 34080025 DOI: 10.3892/mmr.2021.12187] [Reference Citation Analysis]
56 Kondratova AA, Cheon H, Dong B, Holvey-Bates EG, Hasipek M, Taran I, Gaughan C, Jha BK, Silverman RH, Stark GR. Suppressing PARylation by 2',5'-oligoadenylate synthetase 1 inhibits DNA damage-induced cell death. EMBO J 2020;39:e101573. [PMID: 32323871 DOI: 10.15252/embj.2019101573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
57 Stukova M, Hall MD, Tsotsoros SD, Madigan JP, Farrell NP, Gottesman MM. Reduced accumulation of platinum drugs is not observed in drug-resistant ovarian cancer cell lines derived from cisplatin-treated patients. J Inorg Biochem 2015;149:45-8. [PMID: 26021697 DOI: 10.1016/j.jinorgbio.2015.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
58 Zhang X, Li J, Yang Q, Wang Y, Li X, Liu Y, Shan B. Tumor mutation burden and JARID2 gene alteration are associated with short disease-free survival in locally advanced triple-negative breast cancer. Ann Transl Med 2020;8:1052. [PMID: 33145271 DOI: 10.21037/atm-20-3773] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
59 Wang Y, Chen Q, Wu D, Chen Q, Gong G, He L, Wu X. Lamin-A interacting protein Hsp90 is required for DNA damage repair and chemoresistance of ovarian cancer cells. Cell Death Dis 2021;12:786. [PMID: 34381017 DOI: 10.1038/s41419-021-04074-z] [Reference Citation Analysis]
60 Neiger HE, Siegler EL, Shi Y. Breast Cancer Predisposition Genes and Synthetic Lethality. Int J Mol Sci 2021;22:5614. [PMID: 34070674 DOI: 10.3390/ijms22115614] [Reference Citation Analysis]
61 Chowdhury P, Dey P, Ghosh S, Sarma A, Ghosh U. Reduction of metastatic potential by inhibiting EGFR/Akt/p38/ERK signaling pathway and epithelial-mesenchymal transition after carbon ion exposure is potentiated by PARP-1 inhibition in non-small-cell lung cancer. BMC Cancer 2019;19:829. [PMID: 31438892 DOI: 10.1186/s12885-019-6015-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
62 Bi Y, Verginadis II, Dey S, Lin L, Guo L, Zheng Y, Koumenis C. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas. Gynecol Oncol 2018;150:534-44. [PMID: 30025822 DOI: 10.1016/j.ygyno.2018.07.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
63 Høberg-Vetti H, Bjorvatn C, Fiane BE, Aas T, Woie K, Espelid H, Rusken T, Eikesdal HP, Listøl W, Haavind MT, Knappskog PM, Haukanes BI, Steen VM, Hoogerbrugge N. BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. Eur J Hum Genet 2016;24:881-8. [PMID: 26350514 DOI: 10.1038/ejhg.2015.196] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
64 Lee JM, Gordon N, Trepel JB, Lee MJ, Yu M, Kohn EC. Development of a multiparameter flow cytometric assay as a potential biomarker for homologous recombination deficiency in women with high-grade serous ovarian cancer. J Transl Med 2015;13:239. [PMID: 26198537 DOI: 10.1186/s12967-015-0604-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
65 Lavu H, Yeo CJ. Pancreatic ductal adenocarcinoma treatment--the past, present, and future. Semin Oncol. 2015;42:4-7. [PMID: 25726047 DOI: 10.1053/j.seminoncol.2014.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
66 Kim N, Kim SH, Kang SG, Moon JH, Cho J, Suh CO, In Yoon H, Chang JH. ATM mutations improve radio-sensitivity in wild-type isocitrate dehydrogenase-associated high-grade glioma: retrospective analysis using next-generation sequencing data. Radiat Oncol 2020;15:184. [PMID: 32736562 DOI: 10.1186/s13014-020-01619-y] [Reference Citation Analysis]
67 Zimmer AS, Gillard M, Lipkowitz S, Lee JM. Update on PARP Inhibitors in Breast Cancer. Curr Treat Options Oncol 2018;19:21. [PMID: 29644491 DOI: 10.1007/s11864-018-0540-2] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 14.7] [Reference Citation Analysis]
68 Neuzillet C, Tijeras-Raballand A, Bourget P, Cros J, Couvelard A, Sauvanet A, Vullierme MP, Tournigand C, Hammel P. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther. 2015;155:80-104. [PMID: 26299994 DOI: 10.1016/j.pharmthera.2015.08.006] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 9.7] [Reference Citation Analysis]
69 Zhao H, Yang Q, Hu Y, Zhang J. Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple‑negative breast cancer cells. Oncol Rep 2018;40:3223-34. [PMID: 30272286 DOI: 10.3892/or.2018.6716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
70 Hong R, Ma F, Zhang W, Yu X, Li Q, Luo Y, Zhu C, Jiang W, Xu B. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells. BMC Cancer 2016;16:725. [PMID: 27613518 DOI: 10.1186/s12885-016-2754-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
71 de Mestier L, Danset J, Neuzillet C, Rebours V, Cros J, Soufir N, Hammel P. Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers. Endocrine-Related Cancer 2016;23:T57-67. [DOI: 10.1530/erc-16-0269] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
72 Vormoor B, Curtin NJ. Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma. Curr Opin Oncol 2014;26:428-33. [PMID: 24840521 DOI: 10.1097/CCO.0000000000000091] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
73 Gangopadhyay NN, Luketich JD, Opest A, Landreneau R, Schuchert MJ. PARP Inhibitor Activates the Intrinsic Pathway of Apoptosis in Primary Lung Cancer Cells. Cancer Investigation 2014;32:339-48. [DOI: 10.3109/07357907.2014.919303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
74 Martinez-Useros J, Garcia-Foncillas J. The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer. Biomed Res Int 2016;2016:1869304. [PMID: 28078281 DOI: 10.1155/2016/1869304] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
75 Pratz KW, Koh BD, Patel AG, Flatten KS, Poh W, Herman JG, Dilley R, Harrell MI, Smith BD, Karp JE, Swisher EM, McDevitt MA, Kaufmann SH. Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms. Clin Cancer Res 2016;22:3894-902. [PMID: 26979391 DOI: 10.1158/1078-0432.CCR-15-2351] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
76 Fox E, McCuaig J, Demsky R, Shuman C, Chitayat D, Maganti M, Murphy J, Rosen B, Ferguson S, Randall Armel S. The sooner the better: Genetic testing following ovarian cancer diagnosis. Gynecol Oncol 2015;137:423-9. [PMID: 25868966 DOI: 10.1016/j.ygyno.2015.03.057] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
77 George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, Cloke V, Slade I, Kemp Z, Gore M, Strydom A, Banerjee S, Hanson H, Rahman N. Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci Rep 2016;6:29506. [PMID: 27406733 DOI: 10.1038/srep29506] [Cited by in Crossref: 95] [Cited by in F6Publishing: 65] [Article Influence: 19.0] [Reference Citation Analysis]
78 Zyner KG, Mulhearn DS, Adhikari S, Martínez Cuesta S, Di Antonio M, Erard N, Hannon GJ, Tannahill D, Balasubramanian S. Genetic interactions of G-quadruplexes in humans. Elife 2019;8:e46793. [PMID: 31287417 DOI: 10.7554/eLife.46793] [Cited by in Crossref: 42] [Cited by in F6Publishing: 23] [Article Influence: 21.0] [Reference Citation Analysis]
79 Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-ribeiro AB, Xavier CP, Vasconcelos MH. The multi-factorial nature of clinical multidrug resistance in cancer. Drug Resistance Updates 2019;46:100645. [DOI: 10.1016/j.drup.2019.100645] [Cited by in Crossref: 81] [Cited by in F6Publishing: 66] [Article Influence: 40.5] [Reference Citation Analysis]
80 Longerich S, Li J, Xiong Y, Sung P, Kupfer GM. Stress and DNA repair biology of the Fanconi anemia pathway. Blood 2014;124:2812-9. [PMID: 25237197 DOI: 10.1182/blood-2014-04-526293] [Cited by in Crossref: 48] [Cited by in F6Publishing: 37] [Article Influence: 6.9] [Reference Citation Analysis]
81 Hager S, Ackermann CJ, Joerger M, Gillessen S, Omlin A. Anti-tumour activity of platinum compounds in advanced prostate cancer-a systematic literature review. Ann Oncol 2016;27:975-84. [PMID: 27052650 DOI: 10.1093/annonc/mdw156] [Cited by in Crossref: 44] [Cited by in F6Publishing: 31] [Article Influence: 8.8] [Reference Citation Analysis]
82 Eccles DM, Balmaña J, Clune J, Ehlken B, Gohlke A, Hirst C, Potter D, Schroeder C, Tyczynski JE, Gomez Garcia EB. Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review. Adv Ther 2016;33:129-50. [PMID: 26809252 DOI: 10.1007/s12325-016-0281-1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 6.8] [Reference Citation Analysis]
83 Wang X, Shi Y, Huang D, Guan X. Emerging therapeutic modalities of PARP inhibitors in breast cancer. Cancer Treat Rev 2018;68:62-8. [PMID: 29870916 DOI: 10.1016/j.ctrv.2018.05.014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
84 Kohn EC, Ivy SP. Confronting the Care Delivery Challenges Arising from Precision Medicine. Front Oncol 2016;6:106. [PMID: 27200294 DOI: 10.3389/fonc.2016.00106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
85 Begg K, Tavassoli M. Inside the hypoxic tumour: reprogramming of the DDR and radioresistance. Cell Death Discov 2020;6:77. [PMID: 32864165 DOI: 10.1038/s41420-020-00311-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
86 Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R, Chinot OL. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev 2020;86:102017. [PMID: 32335505 DOI: 10.1016/j.ctrv.2020.102017] [Cited by in Crossref: 98] [Cited by in F6Publishing: 83] [Article Influence: 98.0] [Reference Citation Analysis]
87 Sizemore ST, Mohammad R, Sizemore GM, Nowsheen S, Yu H, Ostrowski MC, Chakravarti A, Xia F. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent. Mol Cancer Res 2018;16:1092-102. [PMID: 29592899 DOI: 10.1158/1541-7786.MCR-18-0106] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
88 Tesfaye AA, Kamgar M, Azmi A, Philip PA. The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities. Expert Rev Anticancer Ther. 2018;18:131-148. [PMID: 29254387 DOI: 10.1080/14737140.2018.1417844] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
89 Nageeb AM, Mohamed MM, Ezz El Arab LR, Khalifa MK, Swellam M. Next generation sequencing of BRCA genes in glioblastoma multiform Egyptian patients: a pilot study. Arch Physiol Biochem 2020;:1-9. [PMID: 32100578 DOI: 10.1080/13813455.2020.1729814] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Raman M, Doble M. κ-Carrageenan from marine red algae, Kappaphycus alvarezii – A functional food to prevent colon carcinogenesis. Journal of Functional Foods 2015;15:354-64. [DOI: 10.1016/j.jff.2015.03.037] [Cited by in Crossref: 38] [Cited by in F6Publishing: 13] [Article Influence: 6.3] [Reference Citation Analysis]
91 Jonasson JG, Stefansson OA, Johannsson OT, Sigurdsson H, Agnarsson BA, Olafsdottir GH, Alexiusdottir KK, Stefansdottir H, Munoz Mitev R, Olafsdottir K, Olafsdottir K, Arason A, Stefansdottir V, Olafsdottir EJ, Barkardottir RB, Eyfjord JE, Narod SA, Tryggvadóttir L. Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers. Br J Cancer 2016;115:776-83. [PMID: 27537391 DOI: 10.1038/bjc.2016.249] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
92 Brill E, Yokoyama T, Nair J, Yu M, Ahn YR, Lee JM. Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer. Oncotarget 2017;8:111026-40. [PMID: 29340034 DOI: 10.18632/oncotarget.22195] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 9.5] [Reference Citation Analysis]
93 Scanlon SE, Glazer PM. Multifaceted control of DNA repair pathways by the hypoxic tumor microenvironment. DNA Repair (Amst) 2015;32:180-9. [PMID: 25956861 DOI: 10.1016/j.dnarep.2015.04.030] [Cited by in Crossref: 77] [Cited by in F6Publishing: 63] [Article Influence: 12.8] [Reference Citation Analysis]
94 Fulton AJ, Lamarca A, Nuttall C, McCallum L, Pihlak R, O'Reilly D, Lalloo F, McNamara MG, Hubner RA, Clancy T, Valle JW. Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice. World J Gastrointest Oncol 2019;11:102-16. [PMID: 30788038 DOI: 10.4251/wjgo.v11.i2.102] [Reference Citation Analysis]
95 Wilson RH, Evans TJ, Middleton MR, Molife LR, Spicer J, Dieras V, Roxburgh P, Giordano H, Jaw-Tsai S, Goble S, Plummer R. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. Br J Cancer 2017;116:884-92. [PMID: 28222073 DOI: 10.1038/bjc.2017.36] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 9.5] [Reference Citation Analysis]
96 Oba A, Shimada S, Akiyama Y, Nishikawaji T, Mogushi K, Ito H, Matsumura S, Aihara A, Mitsunori Y, Ban D, Ochiai T, Kudo A, Asahara H, Kaida A, Miura M, Tanabe M, Tanaka S. ARID2 modulates DNA damage response in human hepatocellular carcinoma cells. Journal of Hepatology 2017;66:942-51. [DOI: 10.1016/j.jhep.2016.12.026] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 8.5] [Reference Citation Analysis]
97 Samadder NJ, Giridhar KV, Baffy N, Riegert-Johnson D, Couch FJ. Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes. Mayo Clin Proc 2019;94:1084-98. [PMID: 31171119 DOI: 10.1016/j.mayocp.2019.02.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 18.0] [Reference Citation Analysis]
98 Klemm T, Mannuß A, Kobbe D, Knoll A, Trapp O, Dorn A, Puchta H. The DNA translocase RAD5A acts independently of the other main DNA repair pathways, and requires both its ATPase and RING domain for activity in Arabidopsis thaliana. Plant J 2017;91:725-40. [DOI: 10.1111/tpj.13602] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
99 Bai XT, Moles R, Chaib-Mezrag H, Nicot C. Small PARP inhibitor PJ-34 induces cell cycle arrest and apoptosis of adult T-cell leukemia cells. J Hematol Oncol 2015;8:117. [PMID: 26497583 DOI: 10.1186/s13045-015-0217-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
100 Huh MS, Ivanochko D, Hashem LE, Curtin M, Delorme M, Goodall E, Yan K, Picketts DJ. Stalled replication forks within heterochromatin require ATRX for protection. Cell Death Dis 2016;7:e2220. [PMID: 27171262 DOI: 10.1038/cddis.2016.121] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 8.6] [Reference Citation Analysis]
101 Lim HJ, Ledger W. Targeted therapy in ovarian cancer. Womens Health (Lond) 2016;12:363-78. [PMID: 27215391 DOI: 10.2217/whe.16.4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
102 Gavande NS, VanderVere-Carozza P, Mishra AK, Vernon TL, Pawelczak KS, Turchi JJ. Design and Structure-Guided Development of Novel Inhibitors of the Xeroderma Pigmentosum Group A (XPA) Protein-DNA Interaction. J Med Chem 2017;60:8055-70. [PMID: 28933851 DOI: 10.1021/acs.jmedchem.7b00780] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
103 Nair J, Huang TT, Murai J, Haynes B, Steeg PS, Pommier Y, Lee JM. Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer. Oncogene 2020;39:5520-35. [PMID: 32647134 DOI: 10.1038/s41388-020-1383-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
104 Sharma MB, Carus A, Sunde L, Hamilton-dutoit S, Ladekarl M. BRCA-associated pancreatico-biliary neoplasms: Four cases illustrating the emerging clinical impact of genotyping. Acta Oncologica 2016;55:377-81. [DOI: 10.3109/0284186x.2015.1044023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
105 Venkitaraman AR. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science 2014;343:1470-5. [PMID: 24675954 DOI: 10.1126/science.1252230] [Cited by in Crossref: 145] [Cited by in F6Publishing: 112] [Article Influence: 20.7] [Reference Citation Analysis]
106 AlHilli MM, Becker MA, Weroha SJ, Flatten KS, Hurley RM, Harrell MI, Oberg AL, Maurer MJ, Hawthorne KM, Hou X, Harrington SC, McKinstry S, Meng XW, Wilcoxen KM, Kalli KR, Swisher EM, Kaufmann SH, Haluska P. In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. Gynecol Oncol 2016;143:379-88. [PMID: 27614696 DOI: 10.1016/j.ygyno.2016.08.328] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
107 Ripamonti CB, Manoukian S, Peissel B, Azzollini J, Carcangiu ML, Radice P. Survey of gynecological carcinosarcomas in families with breast and ovarian cancer predisposition. Cancer Genetics 2018;221:38-45. [DOI: 10.1016/j.cancergen.2017.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
108 Kubelac P, Genestie C, Auguste A, Mesnage S, Le Formal A, Pautier P, Gouy S, Morice P, Bentivegna E, Maulard A, Adam J, Achimas-Cadariu P, Leary A. Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer. Cancers (Basel) 2020;12:E707. [PMID: 32192091 DOI: 10.3390/cancers12030707] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
109 Lee JM, Peer CJ, Yu M, Amable L, Gordon N, Annunziata CM, Houston N, Goey AK, Sissung TM, Parker B, Minasian L, Chiou VL, Murphy RF, Widemann BC, Figg WD, Kohn EC. Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer. Clin Cancer Res 2017;23:1397-406. [PMID: 27663600 DOI: 10.1158/1078-0432.CCR-16-1546] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
110 Burstein MD, Tsimelzon A, Poage GM, Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK, Hilsenbeck SG, Chang JC. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21:1688-1698. [PMID: 25208879 DOI: 10.1158/1078-0432.ccr-14-0432] [Cited by in Crossref: 498] [Cited by in F6Publishing: 306] [Article Influence: 71.1] [Reference Citation Analysis]
111 Luo G, Lu Y, Jin K, Cheng H, Guo M, Liu Z, Long J, Liu C, Ni Q, Yu X. Pancreatic cancer: BRCA mutation and personalized treatment. Expert Rev Anticancer Ther 2015;15:1223-31. [PMID: 26402249 DOI: 10.1586/14737140.2015.1086271] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
112 Lynch HT, Lanspa S, Shaw T, Casey MJ, Rendell M, Stacey M, Townley T, Snyder C, Hitchins M, Bailey-Wilson J. Phenotypic and genotypic heterogeneity of Lynch syndrome: a complex diagnostic challenge. Fam Cancer 2018;17:403-14. [PMID: 29071502 DOI: 10.1007/s10689-017-0053-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 7.5] [Reference Citation Analysis]
113 Kiss RC, Xia F, Acklin S. Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment. Int J Mol Sci 2021;22:8199. [PMID: 34360968 DOI: 10.3390/ijms22158199] [Reference Citation Analysis]
114 Sistigu A, Manic G, Obrist F, Vitale I. Trial watch - inhibiting PARP enzymes for anticancer therapy. Mol Cell Oncol 2016;3:e1053594. [PMID: 27308587 DOI: 10.1080/23723556.2015.1053594] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
115 Iyevleva AG, Imyanitov EN. Cytotoxic and targeted therapy for hereditary cancers. Hered Cancer Clin Pract. 2016;14:17. [PMID: 27555886 DOI: 10.1186/s13053-016-0057-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
116 Hayashi H, Higashi T, Miyata T, Yamashita YI, Baba H. Recent advances in precision medicine for pancreatic ductal adenocarcinoma. Ann Gastroenterol Surg 2021;5:457-66. [PMID: 34337294 DOI: 10.1002/ags3.12436] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Chase DM, Patel S, Shields K. Profile of olaparib in the treatment of advanced ovarian cancer. Int J Womens Health 2016;8:125-9. [PMID: 27186080 DOI: 10.2147/IJWH.S55906] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
118 Rojas V, Hirshfield KM, Ganesan S, Rodriguez-Rodriguez L. Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. Int J Mol Sci 2016;17:E2113. [PMID: 27983698 DOI: 10.3390/ijms17122113] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 15.2] [Reference Citation Analysis]
119 Bayraktar S, Arun B. BRCA mutation genetic testing implications in the United States. Breast 2017;31:224-32. [PMID: 27931006 DOI: 10.1016/j.breast.2016.11.021] [Cited by in Crossref: 27] [Cited by in F6Publishing: 10] [Article Influence: 5.4] [Reference Citation Analysis]
120 Partipilo G, Simone G, Scattone A, Scarpi E, Azzariti A, Mangia A. Expression of proteins involved in DNA damage response in familial and sporadic breast cancer patients. Int J Cancer 2016;138:110-20. [PMID: 26205471 DOI: 10.1002/ijc.29699] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
121 Scanlon SE, Hegan DC, Sulkowski PL, Glazer PM. Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in VHL-deficient human renal cell carcinoma. Oncotarget 2018;9:4647-60. [PMID: 29435132 DOI: 10.18632/oncotarget.23470] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
122 Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 2017;18:75-87. [PMID: 27908594 DOI: 10.1016/S1470-2045(16)30559-9] [Cited by in Crossref: 562] [Cited by in F6Publishing: 251] [Article Influence: 112.4] [Reference Citation Analysis]
123 Konecny GE, Kristeleit RS. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Br J Cancer 2016;115:1157-73. [PMID: 27736844 DOI: 10.1038/bjc.2016.311] [Cited by in Crossref: 113] [Cited by in F6Publishing: 83] [Article Influence: 22.6] [Reference Citation Analysis]
124 Frampton JE. Olaparib: a review of its use as maintenance therapy in patients with ovarian cancer. BioDrugs 2015;29:143-50. [PMID: 25899311 DOI: 10.1007/s40259-015-0125-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
125 Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal 2017;10:eaam7479. [PMID: 28536297 DOI: 10.1126/scisignal.aam7479] [Cited by in Crossref: 80] [Cited by in F6Publishing: 65] [Article Influence: 20.0] [Reference Citation Analysis]
126 Benafif S, Hall M. An update on PARP inhibitors for the treatment of cancer. Onco Targets Ther 2015;8:519-28. [PMID: 25750544 DOI: 10.2147/OTT.S30793] [Cited by in Crossref: 17] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
127 Burotto M, Chiou VL, Lee JM, Kohn EC. The MAPK pathway across different malignancies: a new perspective. Cancer 2014;120:3446-56. [PMID: 24948110 DOI: 10.1002/cncr.28864] [Cited by in Crossref: 416] [Cited by in F6Publishing: 337] [Article Influence: 59.4] [Reference Citation Analysis]
128 Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer 2019;18:241-51. [PMID: 30267352 DOI: 10.1007/s10689-018-0106-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
129 Huang X, Motea EA, Moore ZR, Yao J, Dong Y, Chakrabarti G, Kilgore JA, Silvers MA, Patidar PL, Cholka A, Fattah F, Cha Y, Anderson GG, Kusko R, Peyton M, Yan J, Xie XJ, Sarode V, Williams NS, Minna JD, Beg M, Gerber DE, Bey EA, Boothman DA. Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. Cancer Cell 2016;30:940-52. [PMID: 27960087 DOI: 10.1016/j.ccell.2016.11.006] [Cited by in Crossref: 68] [Cited by in F6Publishing: 56] [Article Influence: 17.0] [Reference Citation Analysis]
130 Ghorai A, Sarma A, Chowdhury P, Ghosh U. PARP-1 depletion in combination with carbon ion exposure significantly reduces MMPs activity and overall increases TIMPs expression in cultured HeLa cells. Radiat Oncol 2016;11:126. [PMID: 27659937 DOI: 10.1186/s13014-016-0703-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
131 Severson TM, Wolf DM, Yau C, Peeters J, Wehkam D, Schouten PC, Chin SF, Majewski IJ, Michaut M, Bosma A, Pereira B, Bismeijer T, Wessels L, Caldas C, Bernards R, Simon IM, Glas AM, Linn S, van 't Veer L. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. Breast Cancer Res 2017;19:99. [PMID: 28851423 DOI: 10.1186/s13058-017-0861-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 7.3] [Reference Citation Analysis]
132 Lima ZS, Ghadamzadeh M, Arashloo FT, Amjad G, Ebadi MR, Younesi L. Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms. J Hematol Oncol 2019;12:38. [PMID: 30975222 DOI: 10.1186/s13045-019-0725-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
133 Mosesso P, Piane M, Pepe G, Cinelli S, Chessa L. Modulation of hypersensitivity to oxidative DNA damage in ATM defective cells induced by potassium bromate by inhibition of the Poly (ADP-ribose) polymerase (PARP). Mutation Research/Genetic Toxicology and Environmental Mutagenesis 2018;836:117-23. [DOI: 10.1016/j.mrgentox.2018.05.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
134 Pegram MD, Zong Y, Yam C, Goetz MP, Moulder SL. Innovative Strategies: Targeting Subtypes in Metastatic Breast Cancer. Am Soc Clin Oncol Educ Book 2018;38:65-77. [PMID: 30231328 DOI: 10.1200/EDBK_200715] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
135 Raman M, Devi V, Doble M. Biocompatible ι-carrageenan-γ-maghemite nanocomposite for biomedical applications - synthesis, characterization and in vitro anticancer efficacy. J Nanobiotechnology 2015;13:18. [PMID: 25890231 DOI: 10.1186/s12951-015-0079-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
136 Wang Y, Zeng J, Wu W, Xie S, Yu H, Li G, Zhu T, Li F, Lu J, Wang GY, Xie X, Zhang J. Nicotinamide N-methyltransferase enhances chemoresistance in breast cancer through SIRT1 protein stabilization. Breast Cancer Res 2019;21:64. [PMID: 31101119 DOI: 10.1186/s13058-019-1150-z] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
137 de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov 2017;7:620-9. [PMID: 28242752 DOI: 10.1158/2159-8290.CD-16-1250] [Cited by in Crossref: 192] [Cited by in F6Publishing: 110] [Article Influence: 48.0] [Reference Citation Analysis]
138 Park KS, Lee W, Seong MW, Kong SY, Lee KA, Ha JS, Cho EH, Han SH, Park I, Kim JW. A Population-Based Analysis of BRCA1/2 Genes and Associated Breast and Ovarian Cancer Risk in Korean Patients: A Multicenter Cohort Study. Cancers (Basel) 2021;13:2192. [PMID: 34063308 DOI: 10.3390/cancers13092192] [Reference Citation Analysis]
139 Scott CL, Swisher EM, Kaufmann SH. Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. J Clin Oncol 2015;33:1397-406. [PMID: 25779564 DOI: 10.1200/JCO.2014.58.8848] [Cited by in Crossref: 223] [Cited by in F6Publishing: 125] [Article Influence: 37.2] [Reference Citation Analysis]
140 Peker Eyüboğlu İ, Yenmiş G, Bingöl EN, Yüksel Ş, Tokat F, Özbek P, Güllü Amuran G, Yakıcıer C, Akkiprik M. Next-Generation Sequencing Identifies BRCA1 and/or BRCA2 Mutations in Women at High Hereditary Risk for Breast Cancer with Shorter Telomere Length. OMICS 2020;24:5-15. [PMID: 31851867 DOI: 10.1089/omi.2019.0103] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
141 Tan DS, Kaye SB. Chemotherapy for Patients with BRCA1 and BRCA2-Mutated Ovarian Cancer: Same or Different? Am Soc Clin Oncol Educ Book 2015;:114-21. [PMID: 25993149 DOI: 10.14694/EdBook_AM.2015.35.114] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 4.6] [Reference Citation Analysis]
142 Akashi-Tanaka S, Watanabe C, Takamaru T, Kuwayama T, Ikeda M, Ohyama H, Mori M, Yoshida R, Hashimoto R, Terumasa S, Enokido K, Hirota Y, Okuyama H, Nakamura S. BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy. Clin Breast Cancer 2015;15:80-5. [PMID: 25445419 DOI: 10.1016/j.clbc.2014.08.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
143 Irminger-finger I, Ratajska M, Pilyugin M. New concepts on BARD1: Regulator of BRCA pathways and beyond. The International Journal of Biochemistry & Cell Biology 2016;72:1-17. [DOI: 10.1016/j.biocel.2015.12.008] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 9.0] [Reference Citation Analysis]
144 Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med 2015;13:188. [PMID: 26268938 DOI: 10.1186/s12916-015-0425-1] [Cited by in Crossref: 160] [Cited by in F6Publishing: 129] [Article Influence: 26.7] [Reference Citation Analysis]
145 Borazanci E, Von Hoff DD. Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer. Expert Rev Gastroenterol Hepatol. 2014;8:739-747. [PMID: 24882381 DOI: 10.1586/17474124.2014.925799] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
146 Thomas E, Mohammed S. Advances in Genetic Testing for Hereditary Cancer Syndromes. Recent Results Cancer Res 2016;205:1-15. [PMID: 27075345 DOI: 10.1007/978-3-319-29998-3_1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
147 Barhli A, Cros J, Bartholin L, Neuzillet C. Prognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future. Dig Liver Dis 2018;50:979-90. [PMID: 30205952 DOI: 10.1016/j.dld.2018.08.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
148 van der Biessen DAJ, Gietema JA, de Jonge MJA, Desar IME, den Hollander MW, Dudley M, Dunbar M, Hetman R, Serpenti C, Xiong H, Mittapalli RK, Timms KM, Ansell P, Ratajczak CK, Shepherd SP, van Herpen CML. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. Invest New Drugs 2018;36:828-35. [PMID: 29313279 DOI: 10.1007/s10637-017-0551-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
149 Césaire M, Ghosh U, Austry JB, Muller E, Cammarata FP, Guillamin M, Caruso M, Castéra L, Petringa G, Cirrone GAP, Chevalier F. Sensitization of chondrosarcoma cells with PARP inhibitor and high-LET radiation. J Bone Oncol 2019;17:100246. [PMID: 31312595 DOI: 10.1016/j.jbo.2019.100246] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
150 Krais JJ, Johnson N. BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis. Cancer Res 2020;80:4601-9. [PMID: 32747362 DOI: 10.1158/0008-5472.CAN-20-1830] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
151 Ganguly B, Dolfi SC, Rodriguez-Rodriguez L, Ganesan S, Hirshfield KM. Role of Biomarkers in the Development of PARP Inhibitors. Biomark Cancer 2016;8:15-25. [PMID: 26997874 DOI: 10.4137/BIC.S36679] [Cited by in Crossref: 9] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
152 Zhang B, Ramkumar K, Cardnell RJ, Gay CM, Stewart CA, Wang WL, Fujimoto J, Wistuba II, Byers LA. A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers. Br J Cancer 2021. [PMID: 34294893 DOI: 10.1038/s41416-021-01476-w] [Reference Citation Analysis]
153 Coleman RL, Sill MW, Bell-McGuinn K, Aghajanian C, Gray HJ, Tewari KS, Rubin SC, Rutherford TJ, Chan JK, Chen A, Swisher EM. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015;137:386-91. [PMID: 25818403 DOI: 10.1016/j.ygyno.2015.03.042] [Cited by in Crossref: 155] [Cited by in F6Publishing: 124] [Article Influence: 25.8] [Reference Citation Analysis]
154 Zhu H, Wei M, Xu J, Hua J, Liang C, Meng Q, Zhang Y, Liu J, Zhang B, Yu X, Shi S. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer 2020;19:49. [PMID: 32122376 DOI: 10.1186/s12943-020-01167-9] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 40.0] [Reference Citation Analysis]
155 Fewings E, Larionov A, Redman J, Goldgraben MA, Scarth J, Richardson S, Brewer C, Davidson R, Ellis I, Evans DG, Halliday D, Izatt L, Marks P, McConnell V, Verbist L, Mayes R, Clark GR, Hadfield J, Chin SF, Teixeira MR, Giger OT, Hardwick R, di Pietro M, O'Donovan M, Pharoah P, Caldas C, Fitzgerald RC, Tischkowitz M. Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study. Lancet Gastroenterol Hepatol 2018;3:489-98. [PMID: 29706558 DOI: 10.1016/S2468-1253(18)30079-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 26] [Article Influence: 13.7] [Reference Citation Analysis]
156 Pan Y, Jia LP, Liu Y, Han Y, Li Q, Zou Q, Zhang Z, Huang J, Deng Q. A novel signature of two long non-coding RNAs in BRCA mutant ovarian cancer to predict prognosis and efficiency of chemotherapy. J Ovarian Res 2020;13:112. [PMID: 32950050 DOI: 10.1186/s13048-020-00712-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
157 Lheureux S, Oza AM. Olaparib for the treatment of ovarian cancer. Expert Opinion on Orphan Drugs 2014;2:497-508. [DOI: 10.1517/21678707.2014.899147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
158 Downward J. RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize? Clin Cancer Res 2015;21:1802-9. [PMID: 25878361 DOI: 10.1158/1078-0432.CCR-14-2180] [Cited by in Crossref: 114] [Cited by in F6Publishing: 67] [Article Influence: 22.8] [Reference Citation Analysis]
159 Suh KJ, Ryu HS, Lee K, Kim H, Min A, Kim T, Yang Y, Lee H, Moon H, Han S, Oh D, Han W, Park IA, Noh D, Im S. Prognostic effects of abnormal DNA damage response protein expression in breast cancer. Breast Cancer Res Treat 2019;175:117-27. [DOI: 10.1007/s10549-019-05128-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]